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Normal QRS Duration and Resynchronization
lectrical Signals Applied
uring the Absolute Refractory Period
n Investigational Treatment for Advanced
eart Failure in Patients With Normal QRS Duration
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Cardiac resynchronization therapy has been shown to be an effective treatment for patients
with systolic ventricular dysfunction, prolonged (120 ms) QRS duration, and New York
Heart Association (NYHA) functional class III or IV symptoms despite optimal medical
therapy. However, studies show that a majority of heart failure patients have QRS duration
120 ms. We have been investigating the potential utility of cardiac contractility modulating
(CCM) signals as a treatment option for such patients. Cardiac contractility modulating
signals are non-excitatory signals applied during the absolute refractory period using a
pacemaker-like device that connects to the heart with pacemaker leads. Acute studies carried
out in animals and humans with heart failure suggest that CCM signals can enhance the
strength of left ventricular contraction. Results of initial long-term studies designed mainly to
demonstrate feasibility and provide preliminary indication of safety in patients with medically
refractory NYHA functional class III heart failure are summarized. The results of these
preclinical and clinical studies formed the basis for proceeding with two prospective,
randomized clinical studies currently underway to definitively test the safety and efficacy of
this treatment. (J Am Coll Cardiol 2005;46:2229–36) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.093Cardiology Foundation
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bhe impact of biventricular pacing on ventricular contractile
trength and clinical outcome when applied to patients with
dvanced heart failure and abnormally prolonged activation
as been the topic of active research for over 10 years (1,2).
linical studies have shown that this treatment, referred to
s cardiac resynchronization therapy (CRT), improves pa-
ient symptoms, quality of life, exercise tolerance, and
educes hospitalizations (3,4). The degree of improvement
n ventricular function (quantified by ejection fraction [EF])
mounts to an average 4 percentage points, which is not
pparent immediately, but which appears within six months
f initiating therapy (5). Although use of QRS duration to
redict which patients have mechanical dyssynchrony has
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005, accepted May 10, 2005.een reported as being less than perfect (6,7), and some
tudies suggest that resynchronization may not be the only
echanism leading to clinical improvement (8), QRS du-
ation remains paramount in patient selection. Still, it is
stimated that less than one-half of patients with heart
ailure have a prolonged QRS duration and would therefore
e potentially eligible for treatment with CRT (9,10).
Accordingly, development of a device-based means of
afely enhancing ventricular contractile strength in patients
ith normal activation sequence (i.e., normal QRS dura-
ion) who have advanced heart failure despite optimal
edical therapy could have an important impact. This brief
eview summarizes initial results obtained with such a
reatment currently undergoing investigation based on the
pplication of cardiac contractility modulation (CCM) elec-
rical impulses. The cellular basis for this treatment has been
ecently summarized (11,12). This review focuses on large
nimal and early clinical results.
CM CONCEPT
ne cellular defect that underlies myocardial contractile
ysfunction in heart failure is reduction in the peak and
roadening of the time course of the intracellular calcium
ransient (13). Such abnormalities reflect heart failure-
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CCM Signals for Treatment of Heart Failure December 20, 2005:2229–36ssociated changes in expression of genes encoding calcium-
andling proteins and post-translational modification of
heir associated proteins. Several of the commonly discussed
bnormalities include down-regulation of genes encoding
or the sarcoplasmic reticular adenosine triphosphate–
ependent calcium pump (14–17), changes in expression
nd hypophosphorylation of phopholamban (16–21), al-
ered regulation of the sodium-calcium exchanger
17,22,23), and hyperphosphorylation of the ryanodine
elease channel (24–26). Accordingly, it has been proposed
hat treatments aimed at improving the calcium transient in
eart failure could be therapeutic (27).
Early studies of isolated cardiac muscle showed that use
f voltage clamping techniques to modulate the amplitude
nd duration of membrane depolarization could modulate
alcium entry and contractility in isolated papillary muscles
28–31). Increases in the duration and amplitude of depo-
arization have each been associated with increases in the
trength of cardiac muscle contraction, which have been
inked with increased calcium influx, calcium loading of the
arcoplasmic reticulum, and increased calcium release to the
yofilaments. However, because voltage clamping is not
pplicable to the intact heart, this approach was never
onsidered as a treatment option for heart failure. A
onceptual breakthrough occurred with recognition and
xperimental demonstration in isolated superfused muscle
trips that similar effects could be achieved when extracel-
ular fields with relatively high current densities are applied
ver relatively long durations during the absolute refractory
eriod (Fig. 1) (11). These so-called CCM signals contain
150 times the amount of energy delivered in standard
acemaker impulse. These signals do not initiate the con-
raction, they do not recruit additional contractile elements,
nd there is no additional action potential (as would be
bserved with paired pacing or post-extra systolic potenti-
tion). Cardiac contractility modulation signals are thus
eferred to as non-excitatory.
Borrowing from earlier published reports on voltage
lamping (28–31), several studies were undertaken to in-
estigate contributing mechanisms of the effects of CCM
ignals in isolated superfused muscles. Initial evidence
uggested that CCM signals influence calcium cycling, thus
Abbreviations and Acronyms
CCM  cardiac contractility modulation
CHF  chronic heart failure
CRT  cardiac resynchronization therapy
EF  ejection fraction
ICD  implantable cardioverter-defibrillator
LV  left ventricular
MLWHFQ  Minnesota Living With Heart Failure
Questionnaire
MVO2  myocardial oxygen consumption
NYHA  New York Heart Associationnhancing the strength of the heart beat (11,32). Whether
i
hhis mechanism is in effect during the intermediate (hours)
r long term (days and beyond), signal application is
urrently not known and is the subject of ongoing research.
CM EFFECTS IN NORMAL
ND HEART FAILURE ANIMALS
n vivo field stimulation of entire hearts of larger mam-
als is not feasible because of practical considerations
elated to power availability and nonspecific stimulation
f other tissues (e.g., nerves, skeletal muscles, and so on).
tudies were undertaken to understand the impact of
egional CCM signal delivery on regional contractile
unction and to test the degree to which such signals
ould impact on global contractility (Fig. 2) (33). The
esults indeed showed that CCM signals impact on
yocardial function in the region where they are applied
assessed by regional pressure-segment length loops),
hat these effects are significant enough to exert an
nfluence on the strength of global contractility (as
ssessed by global pressure-volume relationships), and
hat the effects are additive when applied simultaneously
o different regions of the heart.
More importantly, these signals have been shown to
ave a similar effect in animals with heart failure. In one
igure 1. (A) Cardiac contractility modulating (CCM) signals employed
n clinical study are biphasic pulses delivered after a defined delay from
etection of local electrical activation. (B) Effects of CCM signals onsometric force measured from trabecular muscle of an end-stage failing
eart obtained at heart transplant (11,12). ECG  electrocardiogram.
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December 20, 2005:2229–36 CCM Signals for Treatment of Heart Failureeries of experiments, heart failure was induced by
ultiple sequential intracoronary microembolizations
ntil EF was 40% (34,35). Hemodynamic parameters
nd myocardial oxygen consumption (MVO2) were mea-
ured in an open-chest, anesthetized state, with epicardial
lectrodes used to administer CCM signals. Results of
easured parameters are summarized in Table 1 (36).
eart rate and peak left ventricular (LV) pressure did not
hange significantly with CCM therapy. Acute CCM
herapy tended to decrease LV end-diastolic pressure,
hich, after 2 h of continuous CCM therapy, was
tatistically significant. Left ventricular end-diastolic vol-
me did not change with acute CCM therapy, but LV
nd-systolic volume decreased significantly after 1 h.
hus, LV EF increased significantly with CCM therapy
s did cardiac output at both 1 and 2 h of CCM signal
igure 2. Effects of cardiac contractility modulating (CCM) signals on glob
unction in the anterior wall (middle column) and posterior wall (right co
o the anterior wall (top row), posterior wall (middle row), and simultaneo
CM signal application shown in red. LV  left ventricular. Used withal function assessed by pressure-volume relations (left column) and on regional
lumn) assessed by pressure-segment length (SL) loops when signals are applied
usly to both walls (bottom row). Baseline shown in blue; measurements duringpplication. The improvement in LV systolic function
e
sable 1. Hemodynamic and Angiographic Measurements
Mean  SEM)
Baseline 1 h of CCM 2 h of CCM
eart rate (beats/min) 89  3 98  4 93  6
ystolic LV pressure
(mm Hg)
84  4 81  4 80  4
V EDP (mm Hg) 14  2 12  2 11  1*
V EDV (ml) 55  2 52  2 53  3
V ESV (ml) 36  2 31  2* 30  2*
V EF (%) 34  1 40  1* 42  2*
ardiac output (l/min) 1.66  0.04 2.01  0.13* 2.12  0.12*
otal LV CBF (ml/min) 78  13 82  21 89  29
VO2 (mol/min) 213  32 197  56 209  48
V efficiency (%) 22  4 33  17 28  5
p  0.05 vs. baseline.
CBF  coronary blood flow; CCM  cardiac contractility modulation; EDP 
nd-diastolic pressure; EDV  end-diastolic volume; EF  ejection fraction; ESV 
nd-systolic volume; LV  left ventricular; MVO2  myocardial oxygen con-
umption.
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CCM Signals for Treatment of Heart Failure December 20, 2005:2229–36een in this study was accompanied by unchanged total
V coronary blood flow and unchanged MVO2.
NITIAL CLINICAL STUDY OF ACUTE CCM SIGNALS
he initial clinical study of CCM signals involved short-
erm (10- to 30-min) CCM signal application using tem-
orarily placed electrodes in patients with heart failure who
ad a clinical indication for an electrophysiology procedure
such as a CRT and/or implantable cardioverter-
efibrillator [ICD], or a study for evaluation of ventricular
r supraventricular arrhythmias) (37–39). This study in-
olved patients with an average age of 60 11 years with an
verage EF 28  6%, having either ischemic or idiopathic
ardiomyopathy. The findings showed the feasibility of
elivering CCM treatment in humans and demonstrated
hat contractile performance could be enhanced. The signals
ere applied to patients with normal and prolonged QRS
omplexes, and similar acute effects were identified in both
roups (Fig. 3). The data from all patients studied showed
n average10% increase in dP/dtmax that was independent
f baseline QRS duration (Fig. 3A). In a subgroup of the
atients with long QRS, CCM signals were also applied
imultaneously with biventricular pacing; the effects on
cute contractile performance as quantified by dP/dtmax of
RT and CCM were shown to be additive in most patients
Fig. 3B) (38).
igure 3. (A) Acute effects of cardiac contractility modulating (CCM)
ignals on dP/dtmax in patients with heart failure. Average CCM effect
dashed line) was independent of QRS duration. (B) In patients with
rolonged QRS duration, CCM effects were additive to those of biven-m
ricular pacing (BVP) (B) Reprinted from Pappone et al. (38) with
ermission from Excerpta Medica, Inc.Another study examined the impact of acute CCM signal
pplication on MVO2 (40). Patients were instrumented to
easure coronary flow velocity in the left main artery;
uantitative angiography was performed to measure left
ain diameter at the site of velocity measurement (for
alculation of cross-sectional area). Coronary flow was
herefore estimated as the product of velocity and cross-
ectional area. Myocardial oxygen extraction was estimated
rom measurements of arterial and coronary venous blood
O2 and hemoglobin content. Myocardial oxygen con-
umption, in turn, was estimated as the product of oxygen
xtraction and coronary flow. This study was performed in
group of 11 patients, 6 having idiopathic cardiomyopathy,
nd 5 having ischemic cardiomyopathy in whom EF aver-
ged 26  4% and peak VO2 averaged 13.9  2.3 ml
2/kg/min. The results showed that MVO2 was 13.6 
.7 ml O2/min at baseline versus 12.5  7.2 ml O2/min
uring CCM application (p  NS). This was in the setting
f an average 8.8  4.8% increase in dP/dtmax.
EVICE DESCRIPTION AND
MPLANTATION PROCEDURE
N HUMANS FOR ASSESSMENT
F LONG-TERM SAFETY AND EFFICACY
n the clinical setting, CCM signals are delivered to the
eart by an implanted device that looks like a pacemaker
nd connects to the heart via standard commercially avail-
ble pacing leads. The device, called the OPTIMIZER
ystem (41), does not have pacing or antitachycardia ther-
py capabilities but is designed to work in concert with
acemakers and internal defibrillators. The originally inves-
igated systems had a fixed battery, which, because of the
igh energy delivered with each CCM pulse, had longevity
f six to eight months. More recently, a system with a
echargeable battery has been introduced. With this new
ystem, the patient recharges the battery at home once per
eek via a transcutaneous energy transfer charging unit.
The implant procedure itself is also similar to that of a
tandard dual-chamber pacemaker. A pocket is generally
ade in the right subclavian region (a pacemaker/ICD
sually residing on the left subclavian region), and three
lectrodes are introduced into the subclavian vein in a
tandard manner. One electrode is positioned in the right
trium and is used only for sensing atrial activity; this signal
s used in an arrhythmia detection algorithm described
elow to inhibit CCM signal delivery during arrhythmias.
he other two electrodes are positioned on the right
entricular septum. The right ventricular septum can be
hought of as an extension of the LV epicardium. Position-
ng of the electrodes in this location obviates the need for a
otentially lengthy procedure of coronary sinus cannulation
o reach the LV epicardium proper, yet allows for CCM
ignals to influence LV contractile strength to the desired
egree (38). To achieve the desired impact on LV perfor-
ance, CCM signals are delivered through two electrodes.
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December 20, 2005:2229–36 CCM Signals for Treatment of Heart Failurehese electrodes are positioned under fluoroscopic guidance
pproximately half way between the base and apex, one
deally placed near the anterior interventricular groove and
he other near the posterior groove (Fig. 4). In addition to
uoroscopy, proper electrode positioning is confirmed by
easuring a physiologic response to acute CCM signal
pplication through online assessment of changes in LV
P/dtmax (measured via an LV Millar micromanometer,
illar Instruments, Houston, Texas). If initial electrode
lacement does not result in a specified increase in dP/dtmax,
he electrodes are repositioned until such an effect is
chieved. If the desired effect could not be achieved, the
evice was not implanted, and patients were withdrawn
rom the study in which they were enrolled. The estimated
ate of patient withdrawal for this reason is 5% to 10%.
The OPTIMIZER System parameters are set via a
rogrammer that transcutaneously communicates with the
mplanted device. The OPTIMIZER System is designed to
nhibit CCM pulse delivery on arrhythmias. This is to avoid
he possibility that the signal might be delivered during the
ulnerable period (e.g., on a T-wave), which could induce
n arrhythmia. In the present device, this is achieved by
elivering CCM signal only on normal sinus beats, which
re defined as the detection of a P-wave followed by
etection of electrical depolarization at the two right ven-
ricular septal electrodes each within their own specified
iming windows relative to the P-wave. The timing window
or each electrode is programmed for each patient individ-
ally. A future device is planned that incorporates a more
ophisticated arrhythmia detection algorithm that does not
ely on P-wave detection and therefore could be used in
igure 4. Right anterior oblique (RAO) and left lateral oblique (LAO) flu
ne lead is placed in the right atrium (RA), and two leads are placed on
ase and apex, one near the anterior and one near the posterior interventr
eft side of the patient’s body, into the septum. A micromanometer (M
ontractility modulating signal application.atients with atrial fibrillation. eONG-TERM SIGNAL APPLICATION
N PATIENTS WITH NEW YORK HEART
SSOCIATION (NYHA) FUNCTIONAL
LASS III CHRONIC HEART FAILURE (CHF)
he initial experiences with long-term CCM signal appli-
ations were reported in two papers describing results
btained in patients with NYHA functional class III symp-
oms and QRS duration 120 ms (41,42). The studies
escribed in these reports were unblinded, uncontrolled,
reatment only, feasibility studies designed mainly to test
he functionality of the OPTIMIZER System (41,42). The
rst of these papers described interim results of the initial
xperience with the system (42), whereas the second paper
escribed the final results of a formal multicenter study (41).
n the later study, the OPTIMIZER System was implanted
n 23 patients with average age 62  9 years who were
rimarily male (92%) and were split between idiopathic and
schemic cardiomyopathy (41% and 59%, respectively). Base-
ine EF averaged 22  7%, and Minnesota Living With
eart Failure Questionnaire (MLWHFQ) score averaged
3 22. Patients were well medicated with diuretics (88%),
eta-blockers (88%), and angiotensin-converting enzyme
nhibitors (100%). The study revealed that the device
perated as intended, there was no change in ambient
ctopy observed between baseline and eight weeks of treat-
ent, and no overt safety concerns were revealed (Fig. 5).
dditionally, improvements were reported in patient symp-
oms (assessed by NYHA functional class), quality of life
assessed by MLWHFQ), and EF (Fig. 6). Notably, the
egree of improvement in EF reported in this study after
pic images of electrode placement during OPTIMIZER System implant.
ght ventricular septum (RV1, RV2) approximately mid-way between the
groove. The LAO caudal view shows the electrode tips point toward the
is placed temporarily to measure physiologic response to acute cardiacorosco
the ri
icularight weeks of treatment was comparable to those reported
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CCM Signals for Treatment of Heart Failure December 20, 2005:2229–36n response to CRT in patients with prolonged QRS
uration.
To date, completed studies are non-randomized, non-
linded (therefore subject to placebo effect), and with small
ample size. Two multicenter, randomized, controlled stud-
es of CCM are currently underway (one in Europe and one
n the U.S. being performed under an investigational device
xemption from the U.S. Food and Drug Administration)
o definitively test the safety and efficacy of CCM as a
reatment for heart failure. The safety evaluations include
xamination of mortality, hospitalizations, potential proar-
hythmic effects, signs of progressive heart failure, and
verall incidence and severity of adverse events.
OTENTIAL LIMITATIONS
ertain potential limitations evident at this early stage are
oteworthy. First, the device being introduced in the cur-
ently running clinical studies (called the OPTIMIZER III)
s designed to inhibit CCM delivery on arrhythmias and
elies on detection of a P wave as part of the arrhythmia
igure 5. Holter monitor analysis available from the first 22 patients
xposed to cardiac contractility modulating signals for eight weeks showed
o significant change in ambient ectopy quantified by either the average
otal number of premature ventricular contractions (PVCs) per hour of the
verage number of runs of tachycardia consisting of four or more consec-
tive beats of ventricular tachycardia (VT) (41).etection algorithm. Therefore, this device cannot be used
L
fn atrial fibrillation or in patients with a large amount of
mbient ectopy. Second, proper positioning of leads cur-
ently relies on detection of an acute rise in LV dP/dtmax. In
urrent study protocols, the device is not implanted in
atients in whom such a response cannot be demonstrated.
his requirement is not meant to imply any expectation that
cute hemodynamic response will predict long-term clinical
mprovement, only to ensure that the electrodes are in a
osition that can influence myocardium contributing to LV
unction. A simpler method of guiding and confirming
roper lead positioning would be advantageous. Third, the
revious version of the device (the OPTIMZIER II) had a
igure 6. Results of a feasibility study suggest improvements over time in
ew York Heart Association (NYHA) functional classification, Minnesota
iving With Heart Failure Questionnaire (MLWHFQ) score, and ejection
raction over the eight-week course of the study (41).
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December 20, 2005:2229–36 CCM Signals for Treatment of Heart Failureelatively short battery life. This limitation has been over-
ome in the OPTIMIZER III device with introduction of
transcutaneously rechargeable battery. Finally, some pa-
ients have experienced sensation with CCM signal delivery.
erformance of the implant with patients in a non-sedated
tate is intended to minimize the incidence of this effect, but
an still be reported.
UMMARY AND CONCLUSIONS
tudies of CCM signals performed in isolated muscle strips
nd in intact hearts of animals with CHF have suggested
hat these signals can enhance myocardial contractile strength.
ardiac contractility modulation signal delivery with a
acemaker-like device connected to the heart with standard
acing leads has been shown to be straightforward to
mplement clinically. Ongoing basic research focuses on
ew mechanisms by which myocardial properties can be
nfluenced by CCM signals, particularly in the long-term
etting. For example, results of preliminary studies in
nimals suggest that within 6 h of CCM signal delivery
here are significant changes in myocardial gene expression
including a reversal of several aspects of the fetal gene
rogram expressed in heart failure [43,44]), improved ex-
ression and phosphorylation of the sodium-calcium ex-
hanger, phospholamban and connexin 43 (45–50). It is
herefore possible that chronic effects may be independent
f the acute effects discussed in the preceding text both in
erms of their nature and underlying mechanisms.
Preliminary studies in patients have been encouraging.
he overall safety and efficacy of this form of treatment are
eing tested in randomized, controlled clinical trials. If
hese studies show CCM treatment in patients with normal
RS duration to be as safe and effective as CRT in patients
ith prolonged QRS, a new, easily deployable treatment
ill be made available to patients with otherwise untreatable
ymptoms. Future studies could also evaluate whether
CM is effective in patients with wide QRS who declare
hemselves non-responsive to CRT or if combining CRT
ith CCM is more effective than CRT alone. Testing of
hese hypotheses would be facilitated by development of a
ingle device that incorporates pacing, antitachycardia ther-
pies, and CCM.
eprint requests and correspondence: Dr. Hani N. Sabbah,
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